The industry’s focus is on living organisms, and the highly controlled standards make it a unique concern for business leaders. These characteristics also make the industry an ideal source of technological innovation, resulting in major breakthroughs that have boosted agricultural yields, created biofuels and led to life-saving pharmaceutical products.

When you think of strategies to generate revenue biotech startups have a variety of options. The majority opt for a technology partnership or an asset creation-and-out licensing strategy. Technology partnering can result in more revenue and reduce financial risk, whereas outlicensing and asset creation strategies can generate significantly higher returns. A growing number of biotechs at the research stage use an approach that blends the two approaches.

If you choose to go with an approach that is focused on product development can achieve commercial success when they are able to get their pipeline to the appropriate stage and find a pharmaceutical partner or an investor with a large sum of money. This could be a costly venture. It is crucial to balance the opportunistic approach of taking advantage of outside resources and the right scientific decisions regarding domestic projects.

In addition, the “platform” model can provide an alternative route to earning revenue. It is less costly than product-oriented research, but has a significant risk. In this model the biotech official website owns and develops its platform technology prior to partnering with big pharma companies to create a portfolio drug discovery projects that specifically target disease areas (i.e., disease that is x within biology and y). This is the strategy Advinus Therapeutics and a few others have followed.